CD34 and precursor B-cell acute lymphoblastic leukemia: At clinically achievable doses, trametinib and ABT-263 reduced the viability of undifferentiated CD34+/CD19hi cells purified from peripheral blood mononucleated cells of five B-ALL patients, but more importantly, these agents cooperated to further reduce cell viability in these cells (Figure 4a).